S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:IFRX

InflaRx (IFRX) Stock Forecast, Price & News

$4.16
+0.06 (+1.46%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$4.03
$4.20
50-Day Range
$1.67
$6.10
52-Week Range
$0.78
$7.25
Volume
416,600 shs
Average Volume
1.58 million shs
Market Capitalization
$185.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

InflaRx MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
236.5% Upside
$14.00 Price Target
Short Interest
Healthy
1.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of InflaRx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.26) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

327th out of 1,010 stocks

Pharmaceutical Preparations Industry

141st out of 494 stocks


IFRX stock logo

About InflaRx (NASDAQ:IFRX) Stock

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Stock News Headlines

SVB Securities Reaffirms Their Buy Rating on InflaRx (IFRX)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Raymond James Remains a Buy on InflaRx (IFRX)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
LifeSci Capital Reaffirms Their Buy Rating on InflaRx (IFRX)
InflaRx N.V.'s (NASDAQ:IFRX) Profit Outlook
InflaRx (NASDAQ:IFRX) PT Lowered to $9.00 at HC Wainwright
InflaRx Announces Public Offering of Ordinary Shares
InflaRx (NASDAQ:IFRX) Stock Rating Upgraded by Guggenheim
Why Shares of InflaRx Are Soaring Wednesday
See More Headlines
Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Company Calendar

Last Earnings
3/22/2023
Today
5/29/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IFRX
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+236.5%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-31,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.08 per share

Miscellaneous

Free Float
37,417,000
Market Cap
$185.95 million
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Niels Christoph Riedemann
    Chief Executive Officer & Executive Director
  • Thomas Taapken
    Chief Financial Officer
  • Renfeng Guo
    Executive Director & Chief Scientific Officer
  • Maria Habel
    VP, Head-Pre-Clinical Research & Development
  • Bruce P. Burnett
    Vice President & Head-Medical Affairs













IFRX Stock - Frequently Asked Questions

Should I buy or sell InflaRx stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IFRX shares.
View IFRX analyst ratings
or view top-rated stocks.

What is InflaRx's stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price objectives for InflaRx's shares. Their IFRX share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 236.5% from the stock's current price.
View analysts price targets for IFRX
or view top-rated stocks among Wall Street analysts.

How have IFRX shares performed in 2023?

InflaRx's stock was trading at $3.10 on January 1st, 2023. Since then, IFRX shares have increased by 34.2% and is now trading at $4.16.
View the best growth stocks for 2023 here
.

Are investors shorting InflaRx?

InflaRx saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 705,400 shares, a decrease of 26.3% from the April 30th total of 956,900 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 0.3 days.
View InflaRx's Short Interest
.

When is InflaRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IFRX earnings forecast
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) announced its quarterly earnings results on Wednesday, March, 22nd. The company reported ($0.18) earnings per share (EPS) for the quarter.

What ETF holds InflaRx's stock ?

Invesco Raymond James SB-1 Equity ETF holds 63,995 shares of IFRX stock, representing 0.23% of its portfolio.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by many different retail and institutional investors. Top institutional investors include Raymond James Financial Services Advisors Inc. (0.35%), Susquehanna International Group LLP (0.24%), Commonwealth Equity Services LLC (0.20%), JPMorgan Chase & Co. (0.16%) and Raymond James & Associates (0.13%).

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $4.16.

How much money does InflaRx make?

InflaRx (NASDAQ:IFRX) has a market capitalization of $185.95 million. The company earns $-31,070,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The official website for the company is www.inflarx.de. The company can be reached via phone at 493641508180 or via email at jordan.zwick@inflarx.de.

This page (NASDAQ:IFRX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -